Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds
More topics under "C07D - Heterocyclic compounds" (1,537,440)
C07D 201 - Preparation, separation, purification, or stabilisation of unsubstituted lactams (2,192)
C07D 203 - Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom (1,097)
C07D 205 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom (6,868)
C07D 207 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom (40,304)
C07D 209 - Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom (45,780)
C07D 211 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings (37,939)
C07D 213 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members (63,273)
C07D 215 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems (27,676)
C07D 217 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems (11,865)
C07D 219 - Heterocyclic compounds containing acridine or hydrogenated acridine ring systems (2,120)
C07D 221 - Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups (10,931)
C07D 223 - Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom (8,732)
C07D 225 - Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom (1,649)
C07D 227 - Heterocyclic compounds containing rings having one nitrogen atom as the only ring hetero atom, according to more than one of groups (473)
C07D 229 - Heterocyclic compounds containing rings of less than five members having two nitrogen atoms as the only ring hetero atoms (515)
C07D 231 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings (25,550)
C07D 233 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings (34,408)
C07D 235 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings (15,325)
C07D 237 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings (8,468)
C07D 239 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings (42,619)
C07D 241 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings (18,673)
C07D 243 - Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms (5,961)
C07D 245 - Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms (898)
C07D 247 - Heterocyclic compounds containing rings having two nitrogen atoms as the only ring hetero atoms, according to more than one of groups (239)
C07D 249 - Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms (17,749)
C07D 251 - Heterocyclic compounds containing 1,3,5-triazine rings (10,913)
C07D 253 - Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group (2,967)
C07D 255 - Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups (739)
C07D 257 - Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms (9,612)
C07D 259 - Heterocyclic compounds containing rings having more than four nitrogen atoms as the only ring hetero atoms (488)
C07D 261 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings (11,459)
C07D 263 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings (20,978)
C07D 265 - Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms (11,132)
C07D 267 - Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms (2,022)
C07D 269 - Heterocyclic compounds containing rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms according to more than one of groups (111)
C07D 271 - Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms (7,144)
C07D 273 - Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups (2,368)
C07D 275 - Heterocyclic compounds containing 1, 2-thiazole or hydrogenated 1,2-thiazole rings (4,972)
C07D 277 - Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings (33,621)
C07D 279 - Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms (5,149)
C07D 281 - Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms (1,924)
C07D 283 - Heterocyclic compounds containing rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms, according to more than one of groups (102)
C07D 285 - Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups (9,964)
C07D 291 - Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms (1,087)
C07D 293 - Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms (553)
C07D 295 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms (34,005)
C07D 301 - Preparation of oxiranes (10,136)
C07D 303 - Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom (12,512)
C07D 305 - Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms (5,442)
C07D 307 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom (47,108)
C07D 309 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings (12,815)
C07D 311 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings (24,127)
C07D 313 - Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom (3,580)
C07D 315 - Heterocyclic compounds containing rings having one oxygen atom as the only ring hetero atom according to more than one of groups (1,360)
C07D 317 - Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms (18,224)
C07D 319 - Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms (10,283)
C07D 321 - Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups (2,079)
C07D 323 - Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms (1,581)
C07D 325 - Heterocyclic compounds containing rings having oxygen as the only ring hetero atom according to more than one of groups (168)
C07D 327 - Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms (2,428)
C07D 329 - Heterocyclic compounds containing rings having oxygen and selenium or oxygen and tellurium atoms as the only ring hetero atoms (47)
C07D 331 - Heterocyclic compounds containing rings of less than five members, having one sulfur atom as the only ring hetero atom (456)
C07D 333 - Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom (32,883)
C07D 335 - Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom (4,725)
C07D 337 - Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom (875)
C07D 339 - Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms (3,352)
C07D 341 - Heterocyclic compounds containing rings having three or more sulfur atoms as the only ring hetero atoms (281)
C07D 343 - Heterocyclic compounds containing rings having sulfur and selenium or sulfur and tellurium atoms as the only ring hetero atoms (52)
C07D 345 - Heterocyclic compounds containing rings having selenium or tellurium atoms as the only ring hetero atoms (419)
C07D 347 - Heterocyclic compounds containing rings having halogen atoms as ring hetero atoms (38)
C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom (107,979)
C07D 403 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group (62,587)
C07D 405 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom (69,397)
C07D 407 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group (11,963)
C07D 409 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms (52,226)
C07D 411 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms (2,465)
C07D 413 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms (64,687)
C07D 415 - Heterocyclic compounds containing the thiamine skeleton (90)
C07D 417 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group (62,773)
C07D 419 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms (1,431)
C07D 421 - Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms (480)
C07D 451 - Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.02,4] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof (5,273)
C07D 453 - Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids (5,704)
C07D 455 - Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine (2,122)
C07D 457 - Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula: , e.g. lysergic acid (836)
C07D 459 - Heterocyclic compounds containing benz [g] indolo [2, 3-a] quinolizine ring systems, e.g. yohimbine; 16, 18-lactones thereof, e.g. reserpic acid lactone (97)
C07D 461 - Heterocyclic compounds containing indolo [3, 2, 1-d, e] pyrido [3, 2, 1-i, j] [1, 5]-naphthyridine ring systems, e.g. vincamine (286)
C07D 463 - Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (613)
C07D 471 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups (64,559)
C07D 473 - Heterocyclic compounds containing purine ring systems (11,932)
C07D 475 - Heterocyclic compounds containing pteridine ring systems (2,718)
C07D 477 - Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (2,484)
C07D 487 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups (57,272)
C07D 489 - Heterocyclic compounds containing 4ah-8, 9 c- iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: (2,334)
C07D 491 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or (29,726)
C07D 493 - Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system (17,376)
C07D 495 - Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms (21,336)
C07D 497 - Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms (1,069)
C07D 498 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms (21,960)
C07D 499 - Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (3,448)
C07D 501 - Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (7,574)
C07D 503 - Heterocyclic compounds containing 4-oxa-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. oxapenicillins, clavulanic acid derivatives; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (648)
C07D 505 - Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (556)
C07D 507 - Heterocyclic compounds containing a condensed beta-lactam ring system, not provided for by groups , or; Such ring systems being further condensed (161)
C07D 513 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups , or (15,120)
C07D 515 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups , or (877)
C07D 517 - Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms (452)
C07D 519 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or (11,041)
C07D 521 - Heterocyclic compounds containing unspecified hetero rings (16,203)
Patents for C07D - Heterocyclic compounds (10,420)
02/2015
02/03/2015US8945546 IP-10 antibodies and their uses
01/2015
01/28/2015CN102349914B 包含3,4-丙炔基全氢化嘌呤的药物组合物及其在阻滞神经元传递方面的应用 Comprising 3,4-propynyl perhydro purine pharmaceutical compositions and their application in terms of blocking neuronal transfer
01/08/2015US20150011563 Treating Sexual Desire Disorders with Flibanserin
01/01/2015US20150005320 Compounds for inflammation and immune-related uses
12/2014
12/02/2014US8901303 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
12/02/2014US8901130 Low hygroscopic aripiprazole drug substance and processes for the preparation
11/2014
11/20/2014US20140343006 HIV Replication Inhibiting Pyrimidines
11/18/2014US8889681 Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm-related clinical pathologies
11/11/2014US8883889 Pigment compositions comprising pyrrolo[3,4-c]pyrroles
10/2014
10/28/2014US8871763 Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm- related clinical pathologies
10/21/2014US8865720 Sulfonyl-derivatives as novel inhibitors of histone deacetylase
10/16/2014US20140309236 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
10/07/2014US8852890 Production of bacterial strains
10/02/2014US20140296258 Trisubstituted triazolopyrimidines for use in platelet aggregation inhibiton
09/2014
09/30/2014US8846924 Sulfonamide derivatives of polycyclic dyes used for analytical applications
08/2014
08/21/2014US20140235710 CRYSTALLINE FORM OF y-AMINOBUTYRIC ACID ANALOG
08/13/2014CN102050722B 4-联苯基取代的吡唑烷-3,5-二酮衍生物 4-biphenyl substituted pyrazole-3,5-dione derivative
08/07/2014US20140221407 Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm- related clinical pathologies
08/07/2014US20140220590 Methods of using benzothiazole derivative compounds and compositions
07/2014
07/30/2014CN102838675B Ip-10抗体及其用途 Ip-10 antibodies and uses thereof
07/08/2014CA2494715C Method for automated, large-scale measurement of the molecular flux rates using mass spectrometry
07/03/2014US20140187772 Pyrazole compounds useful as protein kinase inhibitors
07/03/2014US20140187576 Salt of naphthyridine carboxylic acid derivative
07/03/2014US20140187530 AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases
06/2014
06/25/2014CN1867322B 结晶形式的γ-氨基丁酸类似物 Crystalline form of γ- aminobutyric acid analogue
06/25/2014CN101759645B p38抑制剂及它们的使用方法 p38 inhibitors and methods for their use
06/12/2014US20140163051 Use and Application of a Pharmaceutical Composition Containing a Mixture of Natural-Origin Heterocyclical Guanidine, For Cosmetology, Wound Healing, Focal Dystonia and Muscular Spasm- Related Clinical Pathologies
06/10/2014US8748476 Darifenacin for use in the treatment of urgency induced by overactive bladder
06/04/2014CN1585772B Chemokine receptor antagonists and methods of use thereof
05/2014
05/13/2014CA2513759C Ceramic based nanoparticles for entrapping therapeutic agents for photodynamic therapy and method of using same
05/01/2014US20140121228 Quinazoline Derivatives as VEGF Inhibitors
04/2014
04/30/2014CN101633655B Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
04/22/2014US8703773 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
04/17/2014US20140107134 Compounds for inflammation and immune-related uses
04/15/2014US8697880 Compounds useful for the synthesis of S- and R-omeprazole and a process for their preparation
04/15/2014US8697698 Pyrazole compounds useful as protein kinase inhibitors
04/08/2014US8691185 Benzothiazole derivative compounds, compositions and uses
04/01/2014US8686034 Crystalline form of γ-aminobutyric acid analog
03/2014
03/04/2014US8663203 Robotic arms DLUs for performing surgical tasks
02/2014
02/27/2014US20140057923 Treating Sexual Desire Disorders with Flibanserin
02/18/2014US8653088 Compositions useful as inhibitors of protein kinases
02/06/2014US20140039215 4-Biphenyl-substituted pyrazolidin-3,5-dione derivatives
02/06/2014US20140038979 Sulfonyl-derivatives as novel inhibitors of histone deacetylase
02/04/2014US8642760 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
02/04/2014US8642608 Quinazoline derivatives as VEGF inhibitors
01/2014
01/30/2014US20140030523 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
01/29/2014CN1914224B HCV NS-3 serine protease inhibitors
01/28/2014US8637497 AZA spiro alkane derivatives as inhibitors of metalloproteases
01/21/2014US8633235 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
01/02/2014US20140005074 Method for automated, large-scale measurement of the molecular flux rates of the proteome or the organeome using mass spectrometry
12/2013
12/31/2013US8618043 Use of ADNF polypeptides for treating anxiety and depression
12/24/2013US8614320 Preparation of aminopyrimidine compounds
12/24/2013US8614317 Sulfonamide derivatives of polycyclic dyes used for analytical applications
12/24/2013CA2500822C Nodulisporic acid derivative spot-on formulations for combating parasites
12/19/2013US20130338148 Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
12/18/2013CN101337900B Method of synthesizing camptothecin-relating compounds
11/2013
11/19/2013US8586783 4-biphenyl-substituted pyrazolidin-3,5-dione derivatives
11/19/2013US8586692 Light protective additive based on organic/inorganic hybrid polymer, method for its manufacture and use thereof
11/14/2013US20130304086 ROBOTIC ARMS DLUs FOR PERFORMING SURGICAL TASKS
11/12/2013US8580796 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
11/05/2013US8575204 Nicotinamide derivates useful as P38 inhibitors
10/2013
10/15/2013US8557825 Sulfonyl-derivatives as novel inhibitors of histone deacetylase
10/15/2013CA2567700C 3-triazolyl-galactoside inhibitors of galectins
10/08/2013US8552016 Anti-cancer cyclopenta(g)quinazoline compounds
09/2013
09/24/2013US8541429 Pyrazolo quinazoline derivatives, process for their preparation and their use as kinase inhibitors
09/24/2013CA2466697C Pharmaceutical compositions containing 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission
09/11/2013CN1665807B Novel physiolgically active substances
09/10/2013US8530655 HIV replication inhibiting pyrimidines
09/10/2013CA2727762C Process for synthesizing thioether precursors of herbicides by reaction of anilines with dialkyl disulfides in the presence of an alkyl nitrite
08/2013
08/28/2013CN103265477A Aminoheteroaryl compounds as protein kinase inhibitors
08/28/2013CN101423492B Aripiprazole anhydride crystal, method for producing the same and medicinal preparation containing the same
08/27/2013US8518983 P38 inhibitors and methods of use thereof
08/20/2013US8512318 Robotic arms DLUs for performing surgical tasks
08/06/2013CA2732620C Crystalline form of 40-o-(2-hydroxy-ethyl) rapamycin and process for preparation thereof
08/06/2013CA2589329E Composition for controlling harmful bio-organisms and method for controlling harmful bio-organisms using the same
07/2013
07/24/2013EP2617419A1 Aza spiro alkane derivatives as inhibitors of metallproteases
07/16/2013US8486955 Anti-cancer cyclopenta [g] quinazoline compounds
07/09/2013US8481478 Method for automated, large-scale measurement of the molecular flux rates of the proteome or the organeome using mass spectrometry
07/09/2013CA2567694C Novel galactoside inhibitors of galectins
07/09/2013CA2518171C Methods and compositions for the enzymatic synthesis of gangliosides
07/04/2013US20130172344 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
07/02/2013US8476286 Quinazoline derivatives which promote the release of parathyroid hormone
07/02/2013CA2540536C Salts and polymorphs of a potent antidiabetic compound
07/02/2013CA2535483C Compositions and methods for reducing the risk of epileptic occurrence and/or for treatment of seizure disorders
06/2013
06/18/2013US8466175 Form of S-omeprazole
06/04/2013CA2545660C Heterocyclic inhibitors of mek and methods of use thereof
06/04/2013CA2545659C Bicyclic inhibitors of mek
05/2013
05/29/2013CN1976934B Alkyl substituted indoloquinoxalines
05/29/2013CN1826121B Use of phenyl and pyridyl derivative for modulating calcium ion-release-activated calcium ion channels
05/28/2013CA2512761C Environmentally benign anti-icing or deicing fluids
05/02/2013US20130109702 Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition
05/01/2013EP1666481B9 3-((3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidinyl)-3-oxo-propionitrile as protein kinase inhibitor
04/2013
04/30/2013US8431574 Heterocyclic inhibitors of MEK and methods of use thereof
04/30/2013CA2517256C Aminoheteroaryl compounds as protein kinase inhibitors
04/18/2013US20130096137 Treating Sexual Desire Disorders with Flibanserin
04/18/2013US20130096128 Pyrazole compounds useful as protein kinase inhibitors
04/09/2013CA2513915C New arylpiperazinyl compounds
04/04/2013US20130081999 Bridged Macrocyclic Module Compositions
04/02/2013CA2533594C Compounds for inflammation and immune-related uses
03/2013
03/27/2013CN1964956B Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
1 2 3 4 5 6 7 8 9 10 11 ... 105